A Phase 1/2 Trial of ASP7487 OSI-906)in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Linsitinib (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2017.
- 08 Dec 2015 Interim analysis results (n=18) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 02 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.